Michael Broder, President, PHAR and Jesse Ortendhal, Director of Health Economics, PHAR give an overview on literature review automation in healthcare.
Scientists and researchers have never been busier. The post-COVID-19 world is driving a high-demand for evidence-based data to support healthcare decisions. An explosion in cost-effectiveness and budget impact modeling studies means systematic literature reviews need to be conducted faster, more accurately, and more efficiently while complying with specific requirements for transparency.
Watch to explore how automated workflows can help ensure screening, classification, and data management are performed faster and more accurately, streamlining the ability for researchers and decision makers to interpret these results and apply them to clinical practices.
Presenters
President
Partnership for Health Analytic Research (PHAR)
Dr. Michael Broder has 30 years' experience in health economic and outcomes research. He has conducted dozens of expert panels on a wide variety of topics. In addition to being an experienced health services researcher, he is a board-certified physician and provides clinical expertise for many studies at PHAR.
Director
Health Economics
Partnership for Health Analytic Research (PHAR)
Jesse Ortendahl has a background in mathematics and statistics and has 20 years’ experience developing disease simulation models for economic evaluations. At PHAR, Jesse conducts and oversees health economic projects using both quantitative and qualitative methods. In addition to traditional cost effectiveness and budget impact models, Jesse has led studies with more policy-relevant goals, such as identifying flaws in current health technology assessment approaches, forecasting the burden of disease and potential policy levers to reduce that burden, and estimating the ramifications of payer policies on cost and clinical outcomes. His work spans a wide range of clinical areas including oncology, cardiology, pulmonology, neurology, and psychiatry.
Production Partner
DistillerSR
DistillerSR automates every stage of the systematic review process for faster and more accurate evidence-based research. More than 300 of the world’s leading pharmaceutical and medical device companies, contract research organizations, governments, NGOs, and academic institutions trust DistillerSR to achieve transparent, audit-ready, and compliant literature reviews.
Additional Content From DistillerSR
Stay Ahead of the Game: Learn How to Conduct an Evidence-Based GVD Faster and Smarter to Improve Market Access
Hear several experts address systematic literature review issues that can negatively affect your Global Value Dossiers (GVDs) and how automation can improve your product's market access.
Streamlining Health Technology Assessments by Automating Literature Reviews
Experts provide a deep dive into what Health Technology Assessment (HTA) agencies do and the types of literature reviews they do.
How Literature Review Automation and Efficient Processes Streamline RWE HEOR Studies
Literature reviews are an essential element in Real World Evidence (RWE) HEOR studies that impact patient care, policy development, and healthcare decision making.
Additional Content From HealthEconomics.Com
Partnering with Disease Registries: The Value and Impact for Real-World Evidence Generation
In this webinar, Evidera experts present guidance on why strong connections with registry groups and stakeholder populations are important for generating relevant real-world evidence to advance treatments.
Minimizing the Impact of Cross-Cultural Differences in COA Translations
ICON's COA Linguistic Validation Leaders highlight the importance of Linguistic Validation and how equivalence should be a key focus during the development of Clinical Outcome Assessment translations.
Improving Patient Outcomes: AI-Based Phenotyping for Diagnosis, Treatment, and Clinical Trials
Watch a panel of OM1’s clinical experts in cardiometabolic disease, immunology, and mental health as they explore how Artificial Intelligence (AI) can find phenotypic patterns and unlock insights hidden in real-world data.
Related Content
Medicare Part D: Price Negotiation Panel Discussion
Hear expert panelists bring their perspectives on critical issues around support for Medicare Part D products' fair market prices.
What Every Researcher Needs to Know About Using Medicare Data for Real World Evidence
Join three panelists who provide a practical overview of how and why to use data from Medicare for real world studies.
Finding Value in Linking Real-World Data with Social Determinants of Health
Hear Pamela Landsman-Blumberg and Rick Chapman highlight the importance of SDOH and discuss examples of how claims data and EMR linked with SDOH can inform use cases.